Secondary Logo

Institutional members access full text with Ovid®

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

Garrido, Carolinaa,b; Tolstrup, Martine; Søgaard, Ole S.e; Rasmussen, Thomas A.e; Allard, Brigittea,b; Soriano-Sarabia, Nataliaa,b; Archin, Nancie M.a,b; Margolis, David M.a,b,c,d

doi: 10.1097/QAD.0000000000002112
BASIC SCIENCE
Buy

Objective: Histone deacetylase inhibitors (HDACi) have proven to induce HIV-RNA and antigen expression in resting CD4+ T cells of antiretroviral therapy (ART)-treated HIV-infected individuals. However, to achieve viral eradication, immune clearance must follow latency reversal, and thus it is essential to understand the impact of latency reversal agents on immune function.

Design: Here we evaluate the impact of in-vivo administration of vorinostat (VOR) and panobinostat (PNB) during clinical trials on natural killer (NK) cell function and phenotype.

Methods: Cryopreserved peripheral blood mononuclear cells from HIV-positive participants receiving VOR (NCT01319383) or PNB (NCT01680094) were selected to assess the impact of the drugs on cell composition, activation, NK cell phenotype (CD16, NKG2D, NKp30, NKp46 and DNAM-1), cytotoxic activity (CD107a), and interferon (IFN)-γ production.

Results: No impairment of NK cell function was observed during treatment with either VOR or PNB. An increase in the frequency of CD3CD56+ NK cells was consistently observed. Interestingly, after VOR administration, NK cells increased expression of NKp46 and CD16, and showed improved degranulation and IFN-γ production capacity. Moreover, taking together VOR and PNB samples, HIV DNA levels in CD4+ cells were negatively correlated with NK cell frequency and NK cell expression of CD16.

Conclusions: In-vivo treatment with HDACi does not have measurable negative effects on NK cell function, with some evidence of improved function in vitro. These results have important implications for potential combinatorial approaches to target HIV reservoirs, suggesting that the use of HDACis as a latency reversal agent could be paired with interventions to enhance NK cell activity or recruitment.

aUNC HIV Cure Center

bDepartment of Medicine

cDepartment of Epidemiology

dDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

eDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Correspondence to Carolina Garrido, University of North Carolina at Chapel Hill, 2013 Genetic Medicine Building, 120 Mason Farm Road, Chapel Hill, NC 27599-7435, USA. Tel: +1 919 966 8415; e-mail: cgarrido@med.unc.edu

Received 20 August, 2018

Accepted 19 November, 2018

Copyright © 2019 Wolters Kluwer Health, Inc.